The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)
Open accessAbstract
BACKGROUND EUCAST has revised the definition of the susceptibility category "I" from "Intermediate" to "Susceptible, Increased exposure". This implies that "I" can be used where the drug-concentration at the site of infection is high, either because of dose escalation or through other means to ensure efficacy. Consequently, "I" is no longer used as a buffer-zone to prevent technical factors from causing misclassifications and discrepancies in interpretations. Instead, an "Area of Technical Uncertainty" (ATU) has been introduced for MICs that cannot be categorised without additional information as a warning to the laboratory that decision on how to act has to be made. To implement these changes, the EUCAST-AFST (Subcommittee on Antifungal Susceptibility Testing) reviewed all, and revised some, clinical antifungal breakpoints. OBJECTIVES To present an overview of the current antifungal breakpoints and supporting evidence behind the changes. SOURCES This document is based on the 10 recently updated EUCAST rationale documents, clinical breakpoint and breakpoint-ECOFF documents. CONTENT The following breakpoints (in mg/L) have been revised or established for Candida species: micafungin against C. albicans (ATU=0.03); amphotericin B (S≤/>R=1/1), fluconazole (S≤/>R=2/4), itraconazole (S≤/>R=0.06/0.06), posaconazole (S≤/>R=0.06/0.06) and voriconazole (S≤/>R=0.06/0.25) against C. dubliniensis; fluconazole against C. glabrata (I≤/>R=16/32); and anidulafungin (S≤/>R=4/4) and micafungin (S≤/>R=2/2) against C. parapsilosis. For Aspergillus, new or revised breakpoints include: itraconazole (ATU=2) and isavuconazole against A. flavus (S≤/>R=1/2, ATU=2); amphotericin B (S≤/>R=1/1), isavuconazole (S≤/>R=1/2, ATU=2), itraconazole (S≤/>R=1/1, ATU=2), posaconazole (ATU=0.25) and voriconazole (S≤/>R=1/1, ATU=2) against A. fumigatus; itraconazole (S≤/>R=1/1, ATU=2) and voriconazole (S≤/>R=1/1, ATU=2) against A. nidulans; amphotericin B against A. niger (S≤/>R=1/1); and itraconazole (S≤/>R=1/1, ATU=2) and posaconazole (ATU=0.25) against A. terreus. IMPLICATIONS EUCAST-AFST has released 10 new documents summarising existing and new breakpoints and MIC-ranges for control strains. A failure to adopt the breakpoint changes may lead to misclassifications and sub-optimal or inappropriate therapy of patients with fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationAnidulafungin versus Fluconazole for Invasive Candidiasis
Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066906 · Cited by 894
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
Self-citationUllmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Self-citationEpidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331
Echinocandin resistance: an emerging clinical problem?
Arendrup, M. C., & Perlin, D. S. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000111 · Cited by 299
Self-citationSipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269
Espinel-Ingroff, A., Arendrup, M. C., Pfaller, M. A., Bonfietti, L. X., Bustamante, B., Canton, E., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Fothergill, A., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01519-13 · Cited by 216
Self-citation
Cited by
Lass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
Self-citationArendrup, M. C., Kahlmeter, G., Guinea, J., & Meletiadis, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.08.042 · Cited by 150
Self-citationEpidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Rogers, T. R., Verweij, P. E., Castanheira, M., Dannaoui, E., White, P. L., Arendrup, M. C., Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST), Arendrup, M. C., Arikan-Akdagli, S., Barchiesi, F., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac161 · Cited by 82
Self-citation
Metadata
- Authors
- Arendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., Mares, M., Kahlmeter, G., Andersen, C. T., Arikan-Akdagli, S., Barchiesi, F., Chryssanthou, E., Hamal, P., Järv, H., Klimko, N., Kurzai, O., Lagrou, K., Lass-Flörl, C., Matos, T., Muehlethaler, K., Rogers, T. R., Velegraki, A., & Arikan, S.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 26
- Issue
- 11
- Pages
- 1464-1472
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W3036059246
- Cited by
- 238
- References
- 18
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). https://app.cochat.ai/papers/10.1016/j.cmi.2020.06.007
- The paper
- Arendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., Mares, M., Kahlmeter, G., Andersen, C. T., Arikan-Akdagli, S., Barchiesi, F., Chryssanthou, E., Hamal, P., Järv, H., Klimko, N., . . . Arikan, S. (2020). How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.06.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.